The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | How are DLL3-targeted T-cell engagers offering promise in SCLC?
Triparna Sen, PhD, The Ohio State University, Columbus, OH, discusses promising data for DLL3-targeted T-cell engagers in small cell lung cancer (SCLC). Dr Sen also describes the mechanism of action of these therapies, highlighting how they can evade the inherent immunosuppression found in SCLC to offer promise beyond immune checkpoint blockade. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
